Chimerix, Inc. has initiated a Phase I study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may allow for a ‘one pill, once-a-day’, fixed-dose combination regimens for the treatment of HIV infection. The Phase I dose-escalating study is designed to evaluate the safet...